The <scp>RAZOR</scp> (randomized open vs robotic cystectomy) trial: study design and trial update
Norm D. Smith(Caris Life Sciences (United States)), Dipen J. Parekh(University of Miami), Ahmad Shabsigh(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Robert S. Svatek(The University of Texas at San Antonio Health Science Center), Alon Z. Weizer(University of Michigan), Tracey L. Krupski(University of Virginia Cancer Center), Marcus L. Quek(Loyola University Medical Center), Badrinath R. Konety(Allina Health), Daniel A. Barocas(Vanderbilt University Medical Center), Matthew K. Tollefson(Mayo Clinic in Arizona), Michael Woods(University of Cambridge), Adam S. Kibel(Brigham and Women's Hospital), Raj S. Pruthi(University of North Carolina at Chapel Hill), Atreya Dash(University of Washington), Mark L. Gonzalgo(University of Miami), Jeffrey S. Montgomery(Ann Arbor Center for Independent Living), Erik P. Castle(WinnMed)
Cited by 80
Related Papers
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2023|592
NCCN Guidelines Insights: Prostate Cancer, Version 1.2021
|Journal of the National Comprehensive Cancer Network|2021|532